Accelerate Diagnostics Inc (AXDX) Shares Bought by Lombard Odier Asset Management USA Corp
Lombard Odier Asset Management USA Corp increased its position in Accelerate Diagnostics Inc (NASDAQ:AXDX) by 420.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 130,094 shares of the medical research company’s stock after acquiring an additional 105,094 shares during the period. Lombard Odier Asset Management USA Corp’s holdings in Accelerate Diagnostics were worth $3,408,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also recently modified their holdings of AXDX. Cpwm LLC purchased a new position in Accelerate Diagnostics in the 4th quarter worth $202,000. UBS Asset Management Americas Inc. purchased a new position in Accelerate Diagnostics in the 4th quarter worth $233,000. Teacher Retirement System of Texas purchased a new position in Accelerate Diagnostics in the 4th quarter worth $292,000. Voya Investment Management LLC raised its stake in Accelerate Diagnostics by 13.9% in the 2nd quarter. Voya Investment Management LLC now owns 12,193 shares of the medical research company’s stock worth $333,000 after acquiring an additional 1,486 shares during the last quarter. Finally, Thompson Investment Management Inc. purchased a new position in Accelerate Diagnostics in the 3rd quarter worth $393,000. Institutional investors own 47.21% of the company’s stock.
A number of equities analysts recently issued reports on AXDX shares. BTIG Research lowered Accelerate Diagnostics from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 13th. They noted that the move was a valuation call. Zacks Investment Research downgraded Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research report on Monday, January 15th. ValuEngine raised Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, BidaskClub raised Accelerate Diagnostics from a “hold” rating to a “buy” rating in a research report on Thursday, February 22nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $33.00.
Accelerate Diagnostics (NASDAQ:AXDX) last announced its quarterly earnings results on Thursday, February 15th. The medical research company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.05. The company had revenue of $2.10 million for the quarter. Accelerate Diagnostics had a negative return on equity of 55.26% and a negative net margin of 1,520.99%. research analysts predict that Accelerate Diagnostics Inc will post -1.2 EPS for the current year.
In related news, Director Jack W. Schuler purchased 10,000 shares of the business’s stock in a transaction on Thursday, February 22nd. The shares were bought at an average cost of $25.21 per share, with a total value of $252,100.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Jack W. Schuler purchased 20,000 shares of the business’s stock in a transaction on Tuesday, February 20th. The shares were bought at an average cost of $24.95 per share, for a total transaction of $499,000.00. The disclosure for this purchase can be found here. 50.00% of the stock is currently owned by company insiders.
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Want to see what other hedge funds are holding AXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accelerate Diagnostics Inc (NASDAQ:AXDX).
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.